Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 3006337 single rising dose in healthy male subjects
NCT05076422Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2021
- Primary completion
- Mar 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 1, randomised, single-blind trial of YH25724 (12 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Number of Subjects With Drug-related Adverse Events at 40 days. Started Oct 2021; status: completed.
02
Drugs
YH25724
Beyond the preview
Go deeper on NCT05076422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05076422.